Literature DB >> 31647182

Potential utility of anti-TNF drugs in synovial chondromatosis associated with ankylosing spondylitis.

Shengyan Yu1, Meifang Wu2, Gengmin Zhou1, Tatsuya Ishikawa2, Jianle Liang3, Dhiraj Nallapothula2, Ram Raj Singh2, Qingwen Wang1, Meiying Wang1,2.   

Abstract

We describe a previously unreported association of ankylosing spondylitis with synovial chondromatosis, and briefly review previously reported cases and treatment of synovial chondromatosis in patients with other immune-mediated inflammatory arthritides. A 20-year-old man with ankylosing spondylitis whose axial disease was in remission with nonsteroidal anti-inflammatory drugs and oral disease-modifying anti-rheumatic drugs developed recurrent right knee pain and swelling. Magnetic resonance imaging of his right knee revealed calcified loose bodies, suggestive of synovial chondromatosis. While waiting for the surgical intervention and other invasive therapy previously reported in patients with synovial chondromatosis, a trial of etanercept eliminated the pain and swelling of the knee; however, the loose bodies have persisted during the 2-year follow-up. Thus, synovial chondromatosis should be considered in the differential diagnoses of a refractory monoarticular pain and swelling in patients with otherwise controlled inflammatory arthritis. Our report advocates a trial of anti-tumor necrosis factor drugs, which might delay the need for invasive therapy in patients with synovial chondromatosis.
© 2019 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  ankylosing spondylitis; etanercept; magnetic resonance imaging; synovial chondromatosis

Mesh:

Substances:

Year:  2019        PMID: 31647182     DOI: 10.1111/1756-185X.13734

Source DB:  PubMed          Journal:  Int J Rheum Dis        ISSN: 1756-1841            Impact factor:   2.454


  1 in total

1.  Synovial Chondromatosis of Hip Joint in a Patient with Ankylosing Spondylitis: A Case Report.

Authors:  Ajay Kumar Yadav; Sujan Raj Paudel; Dilip Kumar Yadav
Journal:  JNMA J Nepal Med Assoc       Date:  2022-05-05       Impact factor: 0.556

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.